Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Those signed the informed consent form and fully understood the study contents, process and possible adverse reactions before participation in the study;~* Those are able to complete the study according to the requirements in the study protocol;~* Those (including the partner) are willing to use effective contraceptions from the screening up to 6 months after the last dose of study drug;~* Male and female subjects aged 18-55 years (inclusive);~* Male subjects no less than 50 kg and female subjects no less than 45 kg. Body mass index (BMI) = body weight (kg)/height2 (m2); BMI: 18-28kg/m2 (inclusive);~* Health status: no clinically significant history of heart, liver, kidney, digestive tract, nervous system, respiratory system diseases, mental disorders or metabolic abnormalities;~* Normal results or clinically insignificant abnormal results in physical examinations and vital sign assessment;~* Positive result of 14C urea breath test (UBT).~Exclusion Criteria:~* Average daily consumption of more than 5 cigarettes within 3 months before the study;~* Allergic constitution (allergy to multiple drugs and food);~* History of drug and/or alcohol abuse (mean consumption of ≥ 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of liquor, or 100 mL of wine);~* History of Helicobacter Pylori eradication;~* Blood donation or massive blood loss (\> 450 mL) within 3 months prior to screening;~* Using any drug that changes liver enzyme activity within 28 days prior to screening;~* Using any prescription drug, over-the-counter drug, any vitamin product, or herbal medicine within 14 days prior to screening;~* Taking special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, or having other factors that affect drug absorption, distribution, metabolism, excretion, etc., within 2 weeks prior to screening;~* Significant changes in diet or exercise habits recently;~* Administration of any other study drug or participation in any drug clinical study within 3 months before administration of the study drug;~* With difficulty in swallowing or history of any gastrointestinal diseases that affect drug absorption;~* With any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers;~* With clinically significant ECG abnormalities;~* Female subjects who are lactating or having positive serum pregnancy test during screening or during the study;~* With symptoms or previous history of cardiovascular, digestive, respiratory, urinary, neurological, hematologic, immunological, endocrine system diseases, tumor, or psychiatric diseases;~* Clinically significant abnormalities in clinical laboratory tests, or other clinically significant findings (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immunological, psychiatric, or cardiovascular disease);~* Positive viral hepatitis (including hepatitis B and C), HIV antigen/antibody, treponema pallidum antibody;~* Acute illness or concomitant medication from the time of signing the informed consent to the time of study medication;~* Intake of chocolate, any caffeine- or xanthine-containing food or drink within 48 hours prior to administration of study drug;~* Intake of any alcohol-containing product within 48 hours before administration of study drug;~* Positive urine drug screening or history of drug abuse or drug addiction within the past 5 years;~* Other conditions that, in the opinion of the investigator, make the patient participating in this study inappropriate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Multiple Ascending Doses Cohort 1 (Type: EXPERIMENTAL): TNP-2198 Capsules 200mg, BID, for 14days
- Multiple Ascending Doses Cohort 2 (Type: EXPERIMENTAL): TNP-2198 Capsules 400mg,BID, for 14days
- Multiple Ascending Doses Cohort 3 (Type: EXPERIMENTAL): TNP-2198 Capsules 600mg,BID, for 14days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete